

# Jennifer T Loud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3377020/publications.pdf>

Version: 2024-02-01

40  
papers

2,375  
citations

331670

21  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

4755  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of first and subsequent cancers among <i>TP53</i> mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. <i>Cancer</i> , 2016, 122, 3673-3681.	4.1	346
2	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
3	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
4	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
5	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. <i>JAMA Oncology</i> , 2017, 3, 1634.	7.1	148
6	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	7.0	138
7	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
8	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
9	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
10	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
11	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	7.1	48
12	Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. <i>JAMA Oncology</i> , 2017, 3, 1640.	7.1	43
13	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( <i>CHEK2</i> ) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	7.1	43
14	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
15	Disclosure of positive <i>BRCA1/2</i> -mutation status in young couples: The journey from uncertainty to bonding through partner support.. <i>Families, Systems and Health</i> , 2008, 26, 296-316.	0.6	36
16	Mosaic chromosome Y loss and testicular germ cell tumor risk. <i>Journal of Human Genetics</i> , 2017, 62, 637-640.	2.3	34
17	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
18	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30

#	ARTICLE	IF	CITATIONS
19	Identification of 22 susceptibility loci associated with testicular germ cell tumors. <i>Nature Communications</i> , 2021, 12, 4487.	12.8	27
20	Ductal Lavage in Women from <i>BRCA1/2</i> Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1243-1251.	2.5	25
21	Rare inactivating <i>PDE11A</i> variants associated with testicular germ cell tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 909-917.	3.1	24
22	Research participant interest in primary, secondary, and incidental genomic findings. <i>Genetics in Medicine</i> , 2016, 18, 1218-1225.	2.4	24
23	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
24	Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 178-193.	1.2	21
25	Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among <i>BRCA1/2</i> carriers.. <i>Health Psychology</i> , 2015, 34, 709-717.	1.6	19
26	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
27	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
28	Deliberate Deceit of Family Members: A Challenge to Providers of Clinical Genetics Services. <i>Journal of Clinical Oncology</i> , 2006, 24, 1643-1646.	1.6	15
29	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	8.2	15
30	Circulating estrogens and estrogens within the breast among postmenopausal <i>BRCA1/2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 517-529.	2.5	13
31	Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. <i>BMC Women's Health</i> , 2009, 9, 20.	2.0	12
32	Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome. <i>European Journal of Cancer</i> , 2019, 116, 199-206.	2.8	10
33	Applications of Advances in Molecular Biology and Genomics to Clinical Cancer Care. <i>Cancer Nursing</i> , 2002, 25, 110-122.	1.5	5
34	Concordance with <i>BRCA1/2</i> testing guidelines among women in The Health of Women (HOW) Study®. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 719-726.	2.5	5
35	Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 159-167.	2.5	5
36	Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1614-1621.	2.5	4

#	ARTICLE	IF	CITATIONS
37	The art and science of cancer nursing in the genomic era. <i>Seminars in Oncology Nursing</i> , 2004, 20, 143-144.	1.5	2
38	Nontesticular cancers in relatives of testicular germ cell tumor (TGCT) patients from multiple TGCT families. <i>Cancer Medicine</i> , 2015, 4, 1069-1078.	2.8	2
39	Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 691-692.	2.5	1
40	Introduction. <i>Seminars in Oncology Nursing</i> , 2017, 33, 119-120.	1.5	0